1. Reimbursable drug classes and ceilings in Italy: why not only one?

   • Livio Garattini
   • Alessandro Curto
   • Anna Padula

   Editorial 02 June 2016 Pages: 923 - 926

   

2. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results

   • Theodoros Mantopoulos
   • Paul M. Mitchell
   • Lazaros Andronis

   Original Paper 07 October 2015 Pages: 927 - 938

   

3. Multiple imputation strategies for zero-inflated cost data in economic evaluations: which method works best?

   • Janet MacNeil Vroomen
   • Iris Eekhout
   • Judith E. Bosmans

   Original Paper Open access 23 October 2015 Pages: 939 - 950

   

4. A cost analysis of orthopedic foot surgery: can outpatient continuous regional analgesia provide the same standard of care for postoperative pain control at home without shifting costs?

   • Andrea Saporito
   • Stefano Calciolari
   • José Aguirre

   Original Paper 14 October 2015 Pages: 951 - 961

   

5. The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study

   • Patrizio Armeni
   • Claudio Jommi
   • Monica Otto

   Original Paper Open access 27 October 2015 Pages: 963 - 977

   

6. The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation

   • Louis S. Matza
   • Kristina S. Boye
   • Jessica Jordan

   Original Paper Open access 26 November 2015 Pages: 979 - 990

7. Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach

   • Elena Nicod
   • Timothy L. Jackson
   • Panos Kanavos

   Original Paper Open access 24 November 2015 Pages: 991 - 999

   

8. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain

   • Manel Mata-Cases
   • Marc Casajuana
   • Bonaventura Bolíbar

   Original Paper Open access 05 November 2015 Pages: 1001 - 1010

9. Is higher nursing home quality more costly?

   • L. Di Giorgio
   • M. Filippini
   • G. Masiero

   Original Paper 26 November 2015 Pages: 1011 - 1026

10. The diffusion of generics after patent expiry in Germany

    • Katharina Elisabeth Fischer
    • Tom Stargardt

    Original Paper 16 November 2015 Pages: 1027 - 1040

    

11. Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature

    • David Epstein
    • Leticia García-Mochón
    • Simon G. Thompson

    Original Paper Open access 18 December 2015 Pages: 1041 - 1053